A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination

Sarah E. Greene; Yuefang Huang; Wooseob Kim; Mariel J. Liebeskind; Vinay Chandrasekaran; Zhuoming Liu; Parakkal Deepak; Michael A. Paley; Daphne Lew; Monica Yang; Mehrdad Matloubian; Lianne S. Gensler; Mary C. Nakamura; Jane A. O'Hallaran; Rachel M. Presti; Sean P.J. Whelan; William J. Buchser; Alfred H.J. Kim; Gary J. Weil

doi:10.1016/j.jcvp.2023.100135

A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination

Sarah E. Greene, Yuefang Huang, Wooseob Kim, Mariel J. Liebeskind, Vinay Chandrasekaran, Zhuoming Liu, Parakkal Deepak, Michael A. Paley, Daphne Lew, Monica Yang, Mehrdad Matloubian, Lianne S. Gensler, Mary C. Nakamura, Jane A. O'Hallaran, Rachel M. Presti, Sean P.J. Whelan, William J. Buchser, Alfred H.J. Kim, Gary J. Weil

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Objective: Lateral flow assays (LFA) are sensitive for detecting antibodies to SARS-CoV-2 proteins within weeks after infection. This study tested samples from immunocompetent adults, and those receiving treatments for chronic inflammatory diseases (CID), before and after mRNA SARS-CoV-2 vaccination. Methods: We compared results obtained with the COVIBLOCK Covid-19 LFA to those obtained by anti-spike (S) ELISA. Results: The LFA detected anti-S antibodies in 29 of 29 (100%) of the immunocompetent and 110 of 126 (87.3%) of the CID participants after vaccination. Semiquantitative LFA scores were statistically significantly lower in samples from immunosuppressed participants, and were significantly correlated with anti-S antibody levels measured by ELISA. Conclusions: This simple LFA test is a practical alternative to laboratory-based assays for detecting anti-S antibodies after infection or vaccination. This type of test may be most useful for testing people in outpatient or resource-limited settings.

Original language	English
Article number	100135
Journal	Journal of Clinical Virology Plus
Volume	3
Issue number	1
DOIs	https://doi.org/10.1016/j.jcvp.2023.100135
State	Published - Feb 2023

Keywords

Antibody test
Immunocompromise
SARS-COV-2
Vaccination

Access to Document

10.1016/j.jcvp.2023.100135

Cite this

Greene, S. E., Huang, Y., Kim, W., Liebeskind, M. J., Chandrasekaran, V., Liu, Z., Deepak, P., Paley, M. A., Lew, D., Yang, M., Matloubian, M., Gensler, L. S., Nakamura, M. C., O'Hallaran, J. A., Presti, R. M., Whelan, S. P. J., Buchser, W. J., Kim, A. H. J., & Weil, G. J. (2023). A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination. Journal of Clinical Virology Plus, 3(1), Article 100135. https://doi.org/10.1016/j.jcvp.2023.100135

@article{c9623fe078fc42d3a9b711d253cb5747,

title = "A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination",

abstract = "Objective: Lateral flow assays (LFA) are sensitive for detecting antibodies to SARS-CoV-2 proteins within weeks after infection. This study tested samples from immunocompetent adults, and those receiving treatments for chronic inflammatory diseases (CID), before and after mRNA SARS-CoV-2 vaccination. Methods: We compared results obtained with the COVIBLOCK Covid-19 LFA to those obtained by anti-spike (S) ELISA. Results: The LFA detected anti-S antibodies in 29 of 29 (100%) of the immunocompetent and 110 of 126 (87.3%) of the CID participants after vaccination. Semiquantitative LFA scores were statistically significantly lower in samples from immunosuppressed participants, and were significantly correlated with anti-S antibody levels measured by ELISA. Conclusions: This simple LFA test is a practical alternative to laboratory-based assays for detecting anti-S antibodies after infection or vaccination. This type of test may be most useful for testing people in outpatient or resource-limited settings.",

keywords = "Antibody test, Immunocompromise, SARS-COV-2, Vaccination",

author = "Greene, {Sarah E.} and Yuefang Huang and Wooseob Kim and Liebeskind, {Mariel J.} and Vinay Chandrasekaran and Zhuoming Liu and Parakkal Deepak and Paley, {Michael A.} and Daphne Lew and Monica Yang and Mehrdad Matloubian and Gensler, {Lianne S.} and Nakamura, {Mary C.} and O'Hallaran, {Jane A.} and Presti, {Rachel M.} and Whelan, {Sean P.J.} and Buchser, {William J.} and Kim, {Alfred H.J.} and Weil, {Gary J.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = feb,

doi = "10.1016/j.jcvp.2023.100135",

language = "English",

volume = "3",

journal = "Journal of Clinical Virology Plus",

issn = "2667-0380",

number = "1",

}

Greene, SE, Huang, Y, Kim, W, Liebeskind, MJ, Chandrasekaran, V, Liu, Z , Deepak, P , Paley, MA , Lew, D, Yang, M, Matloubian, M, Gensler, LS, Nakamura, MC, O'Hallaran, JA, Presti, RM , Whelan, SPJ , Buchser, WJ , Kim, AHJ & Weil, GJ 2023, 'A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination', Journal of Clinical Virology Plus, vol. 3, no. 1, 100135. https://doi.org/10.1016/j.jcvp.2023.100135

TY - JOUR

T1 - A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination

AU - Greene, Sarah E.

AU - Huang, Yuefang

AU - Kim, Wooseob

AU - Liebeskind, Mariel J.

AU - Chandrasekaran, Vinay

AU - Liu, Zhuoming

AU - Deepak, Parakkal

AU - Paley, Michael A.

AU - Lew, Daphne

AU - Yang, Monica

AU - Matloubian, Mehrdad

AU - Gensler, Lianne S.

AU - Nakamura, Mary C.

AU - O'Hallaran, Jane A.

AU - Presti, Rachel M.

AU - Whelan, Sean P.J.

AU - Buchser, William J.

AU - Kim, Alfred H.J.

AU - Weil, Gary J.

PY - 2023/2

Y1 - 2023/2

N2 - Objective: Lateral flow assays (LFA) are sensitive for detecting antibodies to SARS-CoV-2 proteins within weeks after infection. This study tested samples from immunocompetent adults, and those receiving treatments for chronic inflammatory diseases (CID), before and after mRNA SARS-CoV-2 vaccination. Methods: We compared results obtained with the COVIBLOCK Covid-19 LFA to those obtained by anti-spike (S) ELISA. Results: The LFA detected anti-S antibodies in 29 of 29 (100%) of the immunocompetent and 110 of 126 (87.3%) of the CID participants after vaccination. Semiquantitative LFA scores were statistically significantly lower in samples from immunosuppressed participants, and were significantly correlated with anti-S antibody levels measured by ELISA. Conclusions: This simple LFA test is a practical alternative to laboratory-based assays for detecting anti-S antibodies after infection or vaccination. This type of test may be most useful for testing people in outpatient or resource-limited settings.

AB - Objective: Lateral flow assays (LFA) are sensitive for detecting antibodies to SARS-CoV-2 proteins within weeks after infection. This study tested samples from immunocompetent adults, and those receiving treatments for chronic inflammatory diseases (CID), before and after mRNA SARS-CoV-2 vaccination. Methods: We compared results obtained with the COVIBLOCK Covid-19 LFA to those obtained by anti-spike (S) ELISA. Results: The LFA detected anti-S antibodies in 29 of 29 (100%) of the immunocompetent and 110 of 126 (87.3%) of the CID participants after vaccination. Semiquantitative LFA scores were statistically significantly lower in samples from immunosuppressed participants, and were significantly correlated with anti-S antibody levels measured by ELISA. Conclusions: This simple LFA test is a practical alternative to laboratory-based assays for detecting anti-S antibodies after infection or vaccination. This type of test may be most useful for testing people in outpatient or resource-limited settings.

KW - Antibody test

KW - Immunocompromise

KW - SARS-COV-2

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85146728514&partnerID=8YFLogxK

U2 - 10.1016/j.jcvp.2023.100135

DO - 10.1016/j.jcvp.2023.100135

M3 - Article

C2 - 36644774

AN - SCOPUS:85146728514

SN - 2667-0380

VL - 3

JO - Journal of Clinical Virology Plus

JF - Journal of Clinical Virology Plus

IS - 1

M1 - 100135

ER -

A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this